Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
1.160
+0.060 (5.45%)
Dec 20, 2024, 4:00 PM EST - Market closed
Estrella Immunopharma Cash Flow Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Net Income | -8.82 | -7.31 | -11.11 | -1.69 | -0.73 |
| Stock-Based Compensation | - | 1.19 | 0.41 | 0.13 | 0.06 |
| Change in Accounts Payable | -9.33 | -9.33 | 8.39 | - | - |
| Change in Other Net Operating Assets | 0.14 | -0.62 | 0.98 | 0.11 | - |
| Operating Cash Flow | -18.01 | -16.07 | -1.34 | -1.44 | -0.67 |
| Other Investing Activities | 5.07 | 4.96 | -0.27 | - | - |
| Investing Cash Flow | 5.07 | 4.96 | -0.27 | - | - |
| Short-Term Debt Issued | - | 0.3 | - | - | - |
| Total Debt Issued | - | 0.3 | - | - | - |
| Short-Term Debt Repaid | - | -0.3 | - | - | - |
| Total Debt Repaid | -0.3 | -0.3 | - | - | - |
| Issuance of Common Stock | - | 10 | - | 0.02 | - |
| Repurchase of Common Stock | -5.58 | -5.43 | - | - | - |
| Other Financing Activities | -1.53 | -0.8 | - | 0.52 | 0.67 |
| Financing Cash Flow | -7.4 | 12.79 | - | 5.53 | 0.67 |
| Net Cash Flow | -20.34 | 1.69 | -1.61 | 4.09 | - |
| Free Cash Flow | -18.01 | -16.07 | -1.34 | -1.44 | -0.67 |
| Free Cash Flow Per Share | -0.50 | -0.59 | -4.37 | - | - |
| Cash Interest Paid | 0 | 0 | - | - | - |
| Cash Income Tax Paid | 0 | 0 | - | - | - |
| Levered Free Cash Flow | -14.71 | -12.95 | 2.81 | - | - |
| Unlevered Free Cash Flow | -14.71 | -12.95 | 2.81 | - | - |
| Change in Net Working Capital | 9.2 | 9.58 | -9.35 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.